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With the application of genetic testing to contemporary medical diagnostics and practice, it has become apparent 
that the phenotypes of many disorders are modulated by host genetic factors. The aim of the current study was 
to determine whether selected single nucleotide polymorphisms (SNPs) unrelated to the human leukocyte antigen 
region or other immune pathways, including those associated with nonalcoholic fatty liver disease (NAFLD), may 
inf luence development, severity, or outcomes of drug-induced liver injury (DILI). Thirteen variants previously as-
sociated with NAFLD and/or selected other liver diseases were tested in 832 Caucasian DILI cases and 10,397 
Caucasian population controls. DILI cases were attributed to multiple agents (177 individual drugs), with 56 cases 
due to herbal/dietary supplement products. Allele frequencies were imputed from recent genome-wide association 
studies and compared to those for European control samples from the Gnomad database. Significance was tested by 
linear regression or logistic regression, depending on the nature of the trait. Any variant that passed the Bonferroni 
threshold of P  <  0.0004 (0.05
13
) was considered a significant association. None of the variants proved to be signifi-
cantly associated with DILI as phenotype nor with any of the selected severity traits. Among the variants studied, 
rs1421085, found in the fat mass and obesity associated (FTO) gene, showed a marginal protective effect (odds ratio, 
0.8; 95% confidence interval, 0.77-0.95; P  =  0.005). None of the genetic polymorphisms tested were significantly 
associated with the risk of development, severity, or outcome of DILI. Conclusion: SNPs implicated in common liver 
diseases, such as NAFLD, do not play a substantial role in DILI pathogenesis across agents. It remains possible 
that these variants could be involved with DILI due to single agents, but this will require the evaluation of larger 
numbers of bona fide cases. (Hepatology Communications 2019;3:1032-1035).
W ith the application of genetic testing to contemporary medical diagnostics and practice, it has become apparent that the 
phenotypes of many disorders are modulated by host 
genetic factors. For example, the susceptibility to and 
progression of nonalcoholic fatty liver disease (NAFLD) 
have been associated with the p. I148M variant in 
the patatin-like phospholipase domain-containing 
protein 3 (PNPLA3) gene and the p. E167K variant 
of transmembrane 6 super family 2 (TM6SF2).(1,2) In 
Abbreviations: DILI, drug-induced liver injury; DILIN, Drug-Induced Liver Injury Network; FTO, fat mass and obesity associated; NAFLD, 
nonalcoholic fatty liver disease; SNP, single nucleotide polymorphism.
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contrast, susceptibility to idiosyncratic drug-induced 
liver injury (DILI), a rare form of liver disease, has 
been associated primarily with genes that influence 
innate or adaptive immune responses.(3,4)
The aim of the current study was to determine 
whether selected single nucleotide polymorphisms 
(SNPs) unrelated to the human leukocyte antigen region 
or other immune pathways, including those associated 
with NAFLD, may influence development, severity, 
or outcomes of DILI.
Materials and Methods
Thirteen variants previously associated with 
NAFLD and/or selected other liver diseases were 
tested in 832 Caucasian DILI cases and 10,397 
Caucasian population controls (Table 1).(5) DILI cases 
were attributed to multiple agents (177 individual 
drugs), with 56 cases due to herbal/dietary supplement 
products. All cases had DILI Network (DILIN) cau-
sality scores equal to or higher than probable (judged 
51%-100% likely due to a drug). None of the subjects 
from DILIN had been enrolled as acute cases (within 
14 days of onset). Eight variants were imputed from 
the most recent genome-wide association study,(5) and 
four additional variants were directly genotyped only 
in DILI cases, except for the hydroxysteroid dehydro-
genase 17B13 (HSD17B13) splice variant, which was 
typed only in a subset of the DILI cases (n = 384). For 
the latter variants, the allele frequencies for European 
(non-Finnish) control samples in the Gnomad data-
base were used (https ://gnomad.broad insti tute.org/).
The DILI cases were also categorized by severity 
and chronic DILI. Chronic DILI was defined as evi-
dence of ongoing liver injury 6  months after DILI 
onset, as described.(3,5) The significance was tested 
by linear regression or logistic regression, depending 
on the nature of the trait. For genotyped variants and 
binary traits, associations were compared to European 
control samples listed in the Gnomad database and by 
Fisher’s exact test.
Any variant that passed the Bonferroni threshold 
of P < 0.0004 (0.05
13
) was considered a significant asso-
ciation. Follow-up analyses were done for the most 
strongly associated variants by testing in an indepen-
dent Caucasian cohort of 974 DILI cases from the 
International DILI Consortium(5) and in African 
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Americans (169 DILIN cases versus 1,314 controls) 
and Hispanic cohorts (109 DILIN cases and 718 
controls).(5)
Results
None of the variants proved to be significantly asso-
ciated with DILI as phenotype (Table 1) nor with any 
of the selected severity traits (Supporting Table S1). 
Among the variants studied, rs1421085, found in the 
fat mass and obesity associated (FTO) gene, showed a 
marginal protective effect (odds ratio, 0.8; 95% confi-
dence interval, 0.77-0.95; P = 0.005, with similar trends 
also in Hispanic and African-American cohorts), but 
Caucasian replication cases showed a higher frequency 
of the variants (Supporting Table S1).
Discussion
None of the genetic polymorphisms tested were 
significantly associated with the risk of development, 
severity, or outcome of DILI. These data suggest that 
taBle 1. snps inVestigateD in Dilin CauCasian Dili Cases anD population ContRols
Gene Name Genetic Variant
Coding DNA 
Change
Amino Acid 
Change Putative Effect of Variant in NAFLD
DILI Case 
MAF
Control 
MAF P
PNPLA3 rs738409 444C>G I148M Increased hepatocyte triglyceride content 21.1% 23.4% 0.5
rs6006460* 1531G>T S453I Lower than average hepatic  
triglyceride accumulation
0.06% 0.02% 0.2
TM6SF2 rs58542926 499A>G E167K Elevated AST/ALT, increased hepatic 
triglyceride levels, decreased serum 
cholesterol
6.9% 7.5% 0.37
rs10401969 613+80A>G Intron Lower hepatic TM6SF2 mRNA levels  
correlate with larger hepatocellular 
lipid droplets
6.9% 7.7% 0.2
LIPA rs116928232* 894G>A E8SJM Cholesterol ester storage disease often 
resulting in fibrosis→cirrhosis
0.1% 0.1% 1
IFNL4 rs12979860* 151-152G>A Intron Increased degree of hepatic  
inflammation and fibrosis
32.3% 32.0% 0.9
HFE rs1800562 845G>A C282Y Increased hepatic iron uptake,  
associated with greater NAFLD risk/
severity
6.0% 5.5% 0.74
rs1799945 187C>G H63D Increased hepatic iron uptake,  
associated with greater NAFLD risk/
severity
15.3% 15.9% 0.8
HMOX1 rs2071746* –413A>T Affects promoter Higher HMOX1 activity correlated with 
less frequent and less severe NAFLD
42.7% 43.5% 0.9
FTO rs1421085 46-43098T>C Affects repressor Adipocytic phenotype shift from beige 
(energy dissipating) to white (energy 
storing)
38.2% 41.7% 0.005
GNPAT rs11558492 1556A>G D519G Worsened iron overload in patients with 
HFE genetic variations
21.1% 23.3% 0.7
SERPINA1 rs28929474 1096G>A E342K Associated with deficiency of alpha-1 
antitrypsin and with increased risk of 
liver diseases
2% 2% 0.73
HSD17B13 rs72613567† 4:88231392;T>TA Splice variant Associated with a reduced risk of chronic 
liver disease and of progression from 
steatosis to steatohepatitis
28% 27% 0.52
*Variants directly genotyped only in DILI cases; †Variant genotyped only in a subset of the DILI cases (n = 384).
Abbreviations: ALT, alanine, aminotransferase; AST, aspartate aminotransferase; GNPAT, glyceroneophophate O-acyltransferase; 
HFE, homeostatic iron regulator; HMOX1, heme oxygenase 1; HSD17B13, hydroxysteroid 17-beta dehydrogenase 13; IFNL4, inter-
feron lambda 4; LIPA, lipase A, lysosomal acid type 1; MAF, minor allele frequency; mRNA, messenger RNA; PNPLA3, patatin-like 
phospholipase domain-containing protein 3; SERPINA1, serpin peptidase inhibitor, clade A, member 1; TM6SF2, transmembrane 6 
super family 2.
Hepatology CommuniCations, Vol. 3, no. 8, 2019 BONKOVSKY ET AL.
1035
SNPs implicated in common liver diseases, such as 
NAFLD, do not play a substantial role in DILI patho-
genesis across agents. However, it remains possible 
that these variants could be involved with DILI risk 
or outcome due to a single drug, but this will require 
the evaluation of larger numbers of bona fide cases due 
to specific drugs. In addition, rare variants may play a 
role in DILI pathogenesis, but additional studies using 
whole exome or genome testing are required.
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